PMID- 16409195
OWN - NLM
STAT- MEDLINE
DCOM- 20060622
LR  - 20220311
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 61
IP  - 2
DP  - 2006 Feb
TI  - A double-blind, placebo-controlled study of house dust mite immunotherapy in 
      Chinese asthmatic patients.
PG  - 191-7
AB  - BACKGROUND: The purpose of this study was to determine if house dust mite 
      immunotherapy with Alutard SQ is effective in improving symptom control and 
      reducing rescue medication use in Chinese patients with mild to moderate allergic 
      asthma. METHODS: This is a double-blind, placebo-controlled study involving 132 
      asthmatic subjects aged 6-45 years recruited from three different regions of 
      Mainland China. Subjects were given a 52-week course of immunotherapy with 
      Dermatophagoides pteronyssinus extract (Alutard Der p, ALK-Abello, Horsholm, 
      Denmark) or placebo while their dose of inhaled corticosteroids (ICS) was 
      maintained. RESULTS: 129 subjects (64 in active group) completed the study. The 
      symptom scores began to diverge at week 29 with the immunotherapy group showing a 
      significantly lower score until week 48 (P = 0.018). Immunotherapy resulted in a 
      significant decline in symptom (P = 0.002) and medication (P = 0.007) scores 
      during the second half of the treatment period. Both groups showed significant 
      improvement in peak flow rate and bronchial hyperresponsiveness. Serum eosinophil 
      cationic protein (ECP) also decreased in both groups of subjects, but peripheral 
      blood eosinophil count remained unchanged. Skin test response decreased in 
      actively treated subjects only, but Der p-specific immunoglobulin E (IgE) 
      remained unchanged. Immunotherapy resulted in a significantly greater improvement 
      in self-evaluation scores (P < 0.01). CONCLUSIONS: One year treatment with 
      Alutard SQ house dust mite immunotherapy significantly reduced symptoms and 
      medication use in asthmatic subjects. This was associated with a greater 
      subjective improvement in asthma control.
FAU - Wang, H
AU  - Wang H
AD  - Guangzhou Institute of Respiratory Diseases, Guangzhou, China.
FAU - Lin, X
AU  - Lin X
FAU - Hao, C
AU  - Hao C
FAU - Zhang, C
AU  - Zhang C
FAU - Sun, B
AU  - Sun B
FAU - Zheng, J
AU  - Zheng J
FAU - Chen, P
AU  - Chen P
FAU - Sheng, J
AU  - Sheng J
FAU - Wu, A
AU  - Wu A
FAU - Zhong, N
AU  - Zhong N
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Allergens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Allergens/*therapeutic use
MH  - Animals
MH  - Asthma/*prevention & control
MH  - Child
MH  - China
MH  - *Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyroglyphidae/*immunology
MH  - Respiratory Function Tests
EDAT- 2006/01/18 09:00
MHDA- 2006/06/23 09:00
CRDT- 2006/01/18 09:00
PHST- 2006/01/18 09:00 [pubmed]
PHST- 2006/06/23 09:00 [medline]
PHST- 2006/01/18 09:00 [entrez]
AID - ALL913 [pii]
AID - 10.1111/j.1398-9995.2005.00913.x [doi]
PST - ppublish
SO  - Allergy. 2006 Feb;61(2):191-7. doi: 10.1111/j.1398-9995.2005.00913.x.